

Ref no: 082250618
From: Commercial
Date: 25/06/18
Subject: Psoriasis

REQUEST

Within your Trust and over the last three months, how many Psoriasis [PsO] patients have been initiated on their first advanced therapy (i.e. Biologic, Apremilast or Dimethyl fumarate)?

Total New Advanced Therapy patient Initiations.

Where possible please split by treatment;

Adalimumab [Humira]

Apremilast [Otezla]

Brodalumab [Kyntheum]

Certolizumab [Cimzia]

Dimethyl fumarate [Skilarence]

Etanercept [Enbrel]

Etanercept Biosimilar

Guselkumab [Tremfya]

Infliximab [Remicade]

Infliximab Biosimilar

Ixekizumab [Taltz]

Secukinumab [Cosentyx]

Ustekinumab [Stelara]

RESPONSE

From the request of the list of drugs, over the last 3 months, the number of psoriasis patients who have been initiated on their first advanced therapy are:

Adalimumab (Humira) = *

Ustekinumab (stelara) = *

Apremilast = 16

Dimethyl Fumarate = *

The Trust is unable to provide the information you require marked * as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under the Data Protection Act 1998. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the Act.